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SCIENCE & TECHNOLOGY POLICY: A CEO's VIEw
EDWARD PENHOET, PH.D.*
INTRODUCTION
I appreciate the opportunity to address the issues of patents and matters
related to the Food and Drug Administration (FDA), because I think they are
probably the two most important issues that face the biotechnology industry
today. These two issues are not only separately important, but they are
highly interconnected and I am sure you will develop that notion as you read
through this Article.
I am comfortable in writing this Article because my audience seems to
reflect what Chiron Corporation is today: one-third lawyers, one-third
regulatory people, and a few others sprinkled in for good measure. I was
asked to address several issues from the CEO's perspective. One of the
things you learn as a CEO is that you should never pass up an opportunity
to promote something during your talk, so I am going to start with an issue
that has nothing to do with patents or the FDA, but has a lot to do with
California.
THE UNIVERSITY OF CALIFORNIA, THE NIH, AND
THE BIOTECHNOLOGY INDUSTRY
Oftentimes, we focus on problems of national interest and overlook our
obligation to inform our various constituencies of the importance of
biotechnology and other technology related industries. Recently, I had the
opportunity to present a talk to the Board of Regents of the University of
California. Unfortunately, they were as ignorant as most people about how
important biotechnology has become to California and what an extremely
important role biotechnology has played in the development of a large portion
of California's economy. In particular, they seemed to ignore how important
the University of California has been in the development of this entire field.
So Figure 1 simply illustrates the UC connection with the biotechnology
industry.'
* President and Chief Executive Officer of Chiron Corporation, a biotechnology company
headquartered in Emeryville, California. Dr. Penhoet earned his A.B. in Biology from Stanford
University in 1963, and a Ph.D. in Biochemistry from the University of Washington in 1968.
He was a post-doctoral fellow at the University of California, San Diego, from 1968 to 1978.
1. It is particularly appropriate that this Article was originally presented before a meeting
at a UC facility and sponsored, at least in part, by a group of UC people.
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One in three biotechnology companies in the United States, which is
practically one out of three in the world because there are very few
biotechnology companies outside the United States, is within thirty-five miles
of a UC campus. One in six of these companies was started by UC scientists,
including the top three: Genetech, Amgen, and Chiron. Six of the top ten
best-selling biotechnology drugs stem from UC research, most of them
developed by California companies, eighty-five percent of which employ
alumni from the University of California. Thus, there is tremendous
historical cooperation between the University of California and the biotech-
nology industry. Although many of us discuss this issue frequently, it is not
as widely understood as it could be and I think that as we grapple with
problems of significance to the biotechnology industry, we must also continue
to develop programs which further enhance the relationship between the
University of California and the biotechnology industry, especially the
industry within the state of California.
Figure 2 indicates the complexity of the whole field of biotechnology. It
focuses on the role that the public, and the public as represented by many
constituencies, has played in the development of the field.
3
Ph.D.: Science and Technology Policy: A CEO's View
Published by CWSL Scholarly Commons, 1996








California Western Law Review, Vol. 33 [1996], No. 1, Art. 4
https://scholarlycommons.law.cwsl.edu/cwlr/vol33/iss1/4
1996] SCIENCE & TECHNOLOGY POLICY: A CEO'S VIEW 19
As you can see in Figure 2, the government obviously plays an extremely
important role in this field. This is an enormous area that each of us views
from the perspective of our own interests. But stand back and tt to analyze
all the ways in which the government influences business in this country:
local governments decide whether we can build a new laboratory or not; the
state handles this relationship with companies in a variety of different ways;
and at the national level, patents, tax law, and the FDA, all have a profound
influence on the biotechnology industry. These are all extremely important
issues. Of increasing importance is how we handle all of this within the
context of trade and commerce overseas. Thus, the government is truly our
partner in the biotechnology business. There is no question about the fact that
the government influences everything we do. And it begins with government
supported research.
Investors are also extremely important. At its core, this industry is
comprised of two things: science and money. These two things must work
in concert with each other in order to bring useful new products to the
marketplace. The interrelationships between the availability of capital and the
availability of science are extremely important and are highly affected by
patent law and the behavior of the FDA. On the right hand side of Figure 2,
we get closer to the patients, and the way these patient groups are organized
has a strong influence on the capital which is available and coming into the
industry.
If we look for a moment at what have been the key factors in the rise of
biotechnology industries, we arrive at the same conclusion: funding from the
National Institutes on Health (NIH). This is not a forum to discuss NIH
funding, but it is an extremely important part of our industry. For example,
tax laws, such as those pertaining to research and experimentation, have a
measurable and meaningful effect on the research and development pipeline
of products in our industry. Yet they are dwarfed by the subsidy we get as
an industry, and we should call it what it is: It is a federal subsidy to our
industry, supporting primarily NIH funded basic'research in the biomedical
arena.
The reason biotechnology exists in the United States, the reason it thrives
in California, has more to do with NIH funding of academic research than
any other single factor in our industry. It is an indirectly subsidized industry
in the sense that it provides the intellectual framework for the development
of the entire industry. Nevertheless, the reason that biotechnology companies
are located close to University of California campuses is that those campuses
are the wellspring of the new technology which forms the basis of, and in
many cases, the founding and maintenance of these companies.
The reason that biotechnology is primarily a United States phenomenon
is that the United States is where the technology was originally developed.
It is also an area where sufficient capital is available to fund these kinds of
things. These are almost inextricably linked to each other as a phenomenon.
The reason why most multinational health care companies are moving the
base of their research to the United States is that this is where the scientific
5
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base is, and this is a phenomenon particularly true of the UC system for some
time. A majority of the major German pharmaceutical companies are moving
the headquarters of their research firms to the United States. The Swiss
companies are slowly, but surely, doing the same thing. They are not explicit
about it because it causes them political difficulties at home, but more and
more investment by companies from all over the world is being concentrated
in the United States because the intellectual property is located here. Our
intellectual property is still largely resident in NIH funded laboratories around
the country and most of those are obviously within the university environ-
ment. It is important, therefore, that this relationship be maintained, that the
NIH continues to receive adequate funding. This is much more important to
us than are minor enhancements in the tax law intended to benefit research.
For me, it is the most important single issue in terms of the technology that
is continuing to drive our industry.
The investment of the NIH, now close to $12 billion a year, is exceeded
only by the investment of the industry in research and development, which
is about $20 billion a year. There is an important difference between
investments made by the government and those made by the industry itself.
The industry is stepping up the challenge of turning basic research into useful
products by spending more than the government spends. But most of the $20
billion spent by companies today in research and development is development
dollars, not real research dollars. Companies do not engage in much basic
research, so that engine is extremely important to progress. We must never
lose sight of this fact because without the support of the NIH, I think the
industry would be in a much less desirable situation than it is today.
Those at the top of the financial pyramid say technology is what drives
the industry; those at the bottom say you cannot get very far with technology
unless you have the money to develop it. The monetary issue simply shows
that in one company's case, Chiron's, how aggressively we utilize relation-
ships with academic institutions as sources of technology for our company.
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Again, this was for the benefit of the Regents of the University of California,
so the illustration has an obvious bias. Nevertheless, it is also a reality that
more than half of Chiron's support for university based research and
relationships to collectively build value goes to University of California
campuses. That is of course partly due to the fact that I came to Chiron from
UC Berkeley and Bill Rudder came to Chiron from UC San Francisco, but
I think we are fairly typical of people who have migrated in that direction.
This is actually a very small fraction of the total number of relationships that
Chiron has with university laboratories. Today, we have some 500 collabora-
tions with university laboratories.
It is important that those relationships continue to develop, but it is also
important for the technology that arises from those relationships to be
protected by patent. Without patents, the technology has little or no
commercial value. I will return to that point later, but I do think that today,
unfortunately, we do not have the most effective and seamless strategy
between the generators of technology, the universities, and the exploiters of
technology, the companies. We do not have as effective a mechanism for
protecting the overall package of technology generated as we potentially
could have. I think it remains a challenge for us to figure out a better way
to develop communally strong propriety positions. This remains a significant
challenge.
Since its beginning, the biotechnology industry has been totally
dependent on the availability of capital. Unfortunately, the availability of
capital undergoes very wide swings of interest. In the past fifteen years that
I have been involved in this business, we have seen about six cycles of feast
and famine with respect to investment capital. When we started the company
in 1981, it was easy to get funding. Basically, you could stand on a street
comer where some venture capitalists would walk by and say, "I have a Ph.D
in biochemistry, and I want to start a biotech company." You could have
collected the money on a street comer. The next year, just one year later, it
was almost impossible to raise any money. The year following that, there
was again tremendous interest. All biotechnology companies, including
Chiron, went public and raised money. Two years after that, the industry was
again in the doldrums.
To some degree, this scenario is irrational, but it is also predictable
because of the excesses in this field. However, if you look at the availability
of venture capital for biotechnology over a long period of time, you find that
it is driven by factual analysis. Today, factual analysis of the prospects for
commercial success of the biotechnology industry is increasingly important.
There is plenty of capital in the world; the world is awash in capital in a way,
but it is looking for homes around the world where it can be multiplied and
where people can make the best use of the capital. In the United States,
especially in California, these are the kinds of things that affect decisions to
invest in biotechnology.
Health care reform and managed care have clearly been factors which
helped define the marketplace for biotechnology products. As a result, these
[Vol. 33
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products experienced tremendous scrutiny during a time when policymakers
were examining health care costs and the profitability associated with the
industry. Speculation as to regulatory reform made investors nervous about
investing in health care companies, including biotechnology stocks. Thus,
that was a period in which the industry experienced the pressure of a scarcity
of investment capital.
Budget constraints in the United States also affect the underlying
financial support for our industry. We were very fortunate to have modest
increases in NIH funding this year in the budget, 2 but we cannot continue to
count on such increases in the future. We are probably facing a constrained
future with respect to NIH funding for basic research in this country. In spite
of a modest increase this year, the prospects of fairly flat funding for the next
few years after that will force us to live with more constrained funding of
basic biomedical research.
Finally, new technologies obviously impact the public interest whenever
scientists discover something exciting and new that appears to have
commercial utility. One thing we have learned in recent years is that many
in the general public are interested in biotechnology now, so these discoveries
are often published in the newspapers. For example, most of us have read
about the cancer genes discovered recently, as well as a variety of other new
things. The general public learns about new developments in biotechnology
quite quickly and this information tends to stimulate general interest in the
industry. Consolidation from the pharmaceutical industry is an important
element in all of this.
PATENT LAWS AND PROBLEMS
Issues related to patent law, particularly those relating to the General
Agreement on Tariffs and Trade (GATT), the North American Free Trade
Agreement (NAFTA), and the FDA's orphan drug status are extremely
important in determining the availability of capital for biotechnology. In the
past, this has been to some degree an arcane area. Studying patents has never
been something that has appealed much to the general public or to the
investing community. In recent years, however, the patentability of products
in our field has become a dominant factor in analyzing the value that is
created in the biotechnology industry.
As we speak today, we have a situation in biotechnology in which about
85% of all the biotechnology products on the market today are protected by
patents. The largest products--erythropoietin, G-CSF, interferons, (alfa and
beta interferons), hepatitis C tests, tissue plasminogen activator (TPA), and
growth hormone-are all covered by patents. In aggregate, they represent
sales of close to $10 billion a year. It has become a very large industry.
2. See Anthony S. Fauci, Biomedical Research in an Era of Unlimited Aspirations and
Limited Resources, 348 LANCET 1002 (1996).
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However, it is a very small number of products. This $10 billion a year in
sales comes from a relatively small handful of products-only twelve to
fifteen products. Without patents, those twelve products which have sales
close to $10 billion a year today would be likely to have sales close to merely
$1 billion a year. The profitability of this industry, its ability to support
further research and development, and its ability to attract further capital
would be devastated if these products were not afforded patent protection.
If you look at the history of biotechnology, the most important single
factor that has led to the health of the industry today is the realization in the
second half of the 1980s that biotechnology patents would be issued, would
be broad enough to be useful, and would be sustainable in the courts.3 It
took a fair amount of litigation; it still does. Anytime you have anything of
value, people will fight over it-that's a given. But during the period when
biotechnology first started, there were many questions about whether
biotechnology patents were going to have any value. Many remember that
era. In the last half of the 1980s, that question was answered4 : Yes, they
have value. They have value not only in the sense that people can get
patents, but their claims are broad enough that they give them useful
protection in the marketplace,5 and that is what we have to keep our eye on.
If you do not have useful protection in the marketplace, a patent is simply a
lovely piece of paper that you can frame and put on your scientists' CV; but
it has no commercial utility unless it gives protection in the marketplace.
I want to spend a minute on this issue because I think that the most
important positive factor in the past has been the development of utility in the
marketplace. The biggest rut we face as an industry today is the possibility
that utility in the marketplace will be gutted by the agreements we have
reached in the GATT agreements around the world.
Interestingly enough, biotechnology patents have in a strange way
become more valuable than traditional pharmaceutical patents. Historically,
everybody thought that pharmaceutical patents were valuable for protecting
their new chemical entities. But chemical entities tend to be afforded rather
narrow protection, and we learned that they are fairly easy to design around.
The result of this is that the traditional pharmaceutical industry today has
many patented compounds, but tends to sell them in a quasi-generic
marketplace. The interesting thing about knowledge is that if you and I
understand the same set of facts, it is almost always true that we can
independently come up with a unique solution to a problem. With small
molecules and narrow patenting of those molecules, we have seen the
situation where each company in the market of small molecules6 files a
3. Scripps Clinic & Research Found. v. Genetech, Ind., 927 F.2d 1565, 18 U.S.P.Q.2d
(BNA) 1001 (Fed. Cir. 1991).
4. Id.
5. Id
6. E.g., ACE inhibitors and h2 antagonists.
[Vol. 33
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patent on its individual compound. The market then becomes somewhat
generic because there are many similar compounds which do not infringe the
other patents and can therefore also enter the marketplace. So, pharmaceuti-
cal patents have become less valuable and biotechnology patents have become
more valuable because it is much more difficult to engineer around patents
on complex macro-molecules such as proteins.'
From Chiron's perspective, the twenty-year patent term enacted as part
of the GATT agreement8 is devastating to the biotechnology industry. This
bears repeating: In our view, the twenty-year patent term enacted as part of
the GATT agreement is devastating to the biotechnology industry. The
reason for this has to do with timing and the relationship of timing to the
FDA process for approval. First of all, the Patent and Trademark Office
(PTO) is very slow to grant patents in biotechnology. Thus, the biotechnolo-
gy companies face the very real prospect that a patent application may sit in
the PTO for half of its patent term before a patent is actually issued. For
example, we at Chiron discovered hepatitis C in 1987. Today, almost ten
years later, we have only a very narrow patent issued by the PTO on hepatitis
C. This is happening, by the way, in an environment where we have many
patents issued around the world, in Europe and even in Japan.
Half of the newly defined GATT term, which gives twenty years from
the time an application is filed, will have already been used up in the PTO
and we still do not have a patent issued. It is also true that we are in a
highly complex field and we expect that there will be many interferences until
all of this is resolved. Even when you receive a patent, more commonly than
not, it provokes interference from other people who may or may not have
legitimate claims to that technology. Such interference consumes yet another
ten years. It is quite conceivable that the patents on many valuable inventions
will expire before they ever attain a situation where they have market
exclusivity, the very asset which a patent is intended to secure.
We at Chiron strongly support efforts to either create a patent extension
which takes into account the time in the PTO and delays due to interferences
or appeals, or to revive the Dole-Rohrbacher Act9 to restore the seventeen-
year patent life after the patent is issued. We support these efforts because
we can easily foresee a situation where the issuance of some patents will be
delayed, especially for those products which take ten to twelve years,
sometimes longer, to develop. For example, consider beta-interferon, which
we developed with our partners at Schering and Schell as a treatment for
multiple sclerosis. Beta-interferon was cloned and expressed in 1980. It
reached the market for patients suffering from multiple sclerosis in 1994.
7. The larger the molecule, the more difficult it is to determine the relationship between
structure and activity and also the more difficult it is to make non-obvious changes in structure
without losing the desired activity.
8. General Agreement on Tariffs and Trade, opened for signature Oct. 30, 1947, 61 Stat.
pts. 5, 6, T.I.A.S. No. 1700, 55 U.N.T.S. 187.
9. 35 U.S.C. § 154 (1983).
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After fourteen years of hard work, investment, and development, the new
twenty-year patent term would have cut our protection to a mere five years
of market exclusivity for a product that cost us hundreds of millions of
dollars to develop.'" No one is going to undertake a very long development
program in the future if they face the prospect of a long and uncertain
development period, followed by the expiration of the patent clock. People
will discontinue their developments after six or seven years because it is
simply not worth the risk to continue. This will destroy the patent's value
and inhibit the development of useful medicines because people are not going
to undertake these developments if they are not guaranteed adequate
protection when they finish.
Another extremely important issue relates to how we handle the approval
of biotechnology products. This is obviously directly related to the FDA
because of the degree to which the FDA makes the process of approval
cumbersome. One must remember that it is not just getting FDA approval
which makes it cumbersome; rather, it is the whole process from the very
beginning that makes it cumbersome and time-consuming. If we could
streamline the FDA, this problem would be much less acute than it currently
is. It is the long periods required for the FDA, combined with the long
periods required for the patent process, that destroy a product's value in the
end.
The other extremely important patent issue is what happens to our
products overseas. We are in a situation where we allow other countries to
manipulate the patent laws to their own benefit and give such narrow claims
to United States companies so as to destroy the commercial utility. For
example, in Taiwan, a patent office board of appeals recently ruled that
Chiron's HCV patent claims could only cover a diagnostic test, using a
recombinant protein, expressed from a clone obtained from a chimpanzee in
the United States." This does not speak at all to the issue of our invention.
Instead, it speaks to a very narrow and self-serving interpretation of the spirit
of patent laws around the world to help just one municipality.
We think the patent issue has both good and bad associated with it now.
We have had a good history, but we are on the cusp of entering into a terrible
era, and I think we must work extremely hard to avoid that. We view this
as the most important single issue, and it amazes me how little energy and
time, given the importance of this problem, the industry as a whole is
investing in this matter. Nobody seems to want to tackle this issue vigorous-
ly, but it is a tremendously important matter.
The other problem is the FDA. There have been some good develop-
ments happening at the FDA. One very positive thing is the FDA's
willingness to change their manufacturing requirements and approve the so-
10. A new bioengineered drug typically costs $100 million to $150 million to develop.
David I- Olmos, Suitor for Chiron May Be CIBA-GEIGY, L.A. TIMEs, Nov. 15, 1994, at D3.
11. BIOTECHNOLOGY INFORMATION INSTITUTE, HEPATITIS C PATENT DISPUTE (Feb. 1995).
[Vol. 33
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called "well-characterized" biological products.' 2 These changes allow a
company to alter its manufacturing technologies and then so long as the
company can prove it has the same product, sell that product instead of the
one approved with the original manufacturing technology. This speeds up
development because in the past, you had to have a fully developed process
for your molecule in place before you could start clinical trials. If you
wanted to change your process, you had to repeat all of the clinicals. This
is an extremely valuable change in the FDA regulations that will expedite the
process tremendously for biotechnology companies, making approval much
less expensive to pursue.
Although I think this is a very positive move for the FDA, we think the
FDA can move farther. We have seen some movement now in cancer drugs,
getting tentative approvals on the basis of Phase II data 3 showing tumor
shrinkage. 4 It is a very positive move in our regard. We hope that the FDA
will further relax its manufacturing guidelines because many of those
guidelines force us to manufacture our products outside of the United States
instead of manufacturing them here at home. In fact, many companies have
a two-tier system: They manufacture in other countries for products sold
throughout the world, but manufacture in the United States for products sold
in the domestic market. This is tremendously inefficient and consumes
money that could otherwise be utilized for research and development. Chiron
applauds any FDA reforms that make the process more simple and more
straight forward.
We think the federal government, however, does have a legitimate role
to fulfill in ensuring that the American public gets products which are safe
and effective. We are not arguing that the FDA be disbanded entirely in
favor of a free market for these products. That would go beyond what we
would like to see. But there is a tremendous opportunity for simplification
and better scientific tools to enhance such simplification.
12. "Well-characterized" biological products are those biotech products whose "identity,
purity, impurities, potency and quality can be determined and controlled." Steve Sterberg, Three
Days of Debate Yields Possible Consensus on FDA Definition for Biotech Products, Bioworld
Today, Dec. 14, 1995, available in LEXIS, NEXIS Library, Magazine file.
13. Phase II includes the controlled clinical studies conducted to evaluate the effectiveness
of the drug for a particular indication or indications in patients with the disease or condition
under study and to determine the common short-term side effects and risks associated with the
drug. 21 C.F.R. § 312.21 (1996).
14. Biotech Financing in First Quarter '96 Outpace Prior Three Months, Exceeding $1.6
Billion, P.R. NEvsxvmE, Apr. 4, 1996.
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TAXES AND THE BIOTECHNOLOGY INDUSTRY
The final issue of importance is taxation. The federal research and
experimental credits legislation 5 is a benefit, although not a tremendous
benefit for most biotechnology companies. There are many issues in the way
it is calculated, with a so-called base that is determined by sales.' 6 Most
early stage biotechnology companies do not have any sales. This results in
a very uneven utilization of this tax credit. Unfortunately, most of the
benefits from this credit do not go to truly innovative companies. It would
be nice if these types of tax credits actually stimulated innovation instead of
giving benefits to large companies. It clearly has not worked tremendously
well. The United States investment in research and development has shrunk
from 3% a decade ago to 2.6%. in the last year, 7 so we need to do a better
job of stimulating research and development. I am not sure that this tax
credit alone will be a major factor in this; but it has certainly been helpful.
Finally, most biotechnology products today are quickly utilized around
the world and, therefore, many successful biotechnology companies set up
international operations. We have to be careful that our tax laws do not
stimulate those companies to invest in overseas research and development,
rather than in the United States. It is quite technical, but there are some
aspects of tax deferral for foreign subsidiaries that encourage United States
companies to go incur research and development expenditures outside of the
United States so that they can get tax benefits in those local environments.
Because of this, I believe there will be a trend to do more research and
development in Europe. Currently, everyone is coming to the United States,
but at the same time, there are some big benefits now for doing research and
development in Europe"8 and those benefits will increase in the future. We
as a nation must try to keep as much research and development as we can
domestically, and not create tax situations that encourage organizations to
move their research and development operations outside of the United States.
15. 26 U.S.C. § 41 (1996).
16. The section 41 credit is incremental, amounting to 20% of the excess of current qualified
research expenses over a base equal to the mean of qualified research and experimental
expenditures for the preceding three years. Id. at § 41(a)(1)(c). If there have been no research
and experimental expenditures in any of the preceding three years, the base is 50% of the current
year's expenditures. Id. at § 41(c)(3).
17. See Gattelle, R&D Magazine Forecast Predicts Small Increase in R&D Expenditures
for 1996, ELECTRO MANUFACURING, available in LEXIS, News Library, Magazine File.
18. One benefit, for example, is that it is easier to initiate human trials. Also, the trials cost
significantly less because hospital and physician services costs are significantly lower in Europe
than they are in the United States.
[Vol. 33
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CONCLUSION
So, that's my soap box for the time being. I was asked to give a CEO's
perspective, and that's what I've tried to do. I appreciate this opportunity.
I think that it is important that those at the United States Patent and
Trademark Office fully understand the effects of the twenty-year patent.
Although what they have done appears to be quite logical and nothing is
inherently wrong, I think that they do not truly understand the double bind
we are in as a result. Therefore, I think communication is an important issue.
I think we need to press all of our organizations, Biotechnology Industry
Organization 9 and otherwise, to work even harder on this matter than they
already have. Some of my colleagues have been somewhat intimidated about
this matter because it has a lot of political support from other industries in the
United States, but I think just promoting the realization among our colleagues
of the urgency of this issue is really important because the twenty-year patent
term and NAFTA as part of the GATT agreement is devastating to the
biotechnology industry. Unless meaningful reforms are initiated soon, the
United States' progress in biotechnology will be greatly retarded.
19. The Biotechnology Industry Organization (BIO) is a major trade association comprised
of approximately 560 biotechnology companies.
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